Amgen Inc. Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One
Amgen Inc. (AMGN) had Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One of $5.85 billion as of 2022-03-31, per its 10-Q filed 2022-04-28.
Discontinued › Notes › Investments › Debt and Equity Securities › Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity › Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value
us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue · last filed 2022-04-28
- 2022-03-31: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $5.85B.
- 2021-12-31: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $7.30B.
- 2021-09-30: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $12.28B.
- 2021-06-30: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $7.16B.
| Period end | Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One | Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One as first filed |
|---|---|---|
| 2022-03-31 | $5.85B 10-Q · filed 2022-04-28 | |
| 2021-12-31 | $7.30B 10-Q · filed 2022-04-28 | |
| 2021-09-30 | $12.28B 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $7.16B 10-Q · filed 2021-08-04 | |
| 2021-03-31 | $9.71B 10-Q · filed 2021-04-28 | |
| 2020-12-31 | $9.79B 10-K · filed 2022-02-16 | |
| 2020-09-30 | $11.54B 10-Q · filed 2020-10-29 | |
| 2020-06-30 | $10.68B 10-Q · filed 2020-07-29 | |
| 2020-03-31 | $7.17B 10-Q · filed 2020-05-01 | |
| 2019-12-31 | $5.63B 10-K · filed 2021-02-09 | |
| 2019-09-30 | $12.94B 10-Q · filed 2019-10-30 | |
| 2019-06-30 | $9.87B 10-Q · filed 2019-07-31 | |
| 2019-03-31 | $14.36B 10-Q · filed 2019-05-01 | |
| 2018-12-31 | $17.42B 10-K · filed 2020-02-12 | |
| 2018-09-30 | $17.94B 10-Q · filed 2018-10-31 | |
| 2018-06-30 | $13.27B 10-Q · filed 2018-07-27 | |
| 2017-12-31 | $6.73B 10-K · filed 2019-02-13 | |
| 2016-06-30 | $3.96B 10-Q · filed 2016-07-29 | |
| 2016-03-31 | $4.18B 10-Q · filed 2016-05-02 | |
| 2015-12-31 | $4.58B 10-Q · filed 2016-07-29 | |
| 2015-09-30 | $3.86B 10-Q · filed 2015-11-02 | |
| 2015-06-30 | $4.70B 10-Q · filed 2015-08-05 | |
| 2015-03-31 | $4.01B 10-Q · filed 2015-04-27 | |
| 2014-12-31 | $4.94B 10-K · filed 2016-02-16 | |
| 2014-09-30 | $5.10B 10-Q · filed 2014-10-29 | |
| 2014-06-30 | $5.82B 10-Q · filed 2014-08-05 | |
| 2014-03-31 | $7.11B 10-Q · filed 2014-04-30 | |
| 2013-12-31 | $6.80B 10-K · filed 2015-02-19 | |
| 2013-09-30 | $10.82B 10-Q · filed 2013-10-29 | |
| 2013-06-30 | $6.81B 10-Q · filed 2013-08-06 | |
| 2013-03-31 | $3.92B 10-Q · filed 2013-05-03 | |
| 2012-12-31 | $7.17B 10-K · filed 2014-02-24 | |
| 2012-09-30 | $8.50B 10-Q · filed 2012-11-06 | |
| 2012-06-30 | $6.46B 10-Q · filed 2012-08-08 | |
| 2012-03-31 | $4.00B 10-Q · filed 2012-05-08 | |
| 2011-12-31 | $6.79B 10-K · filed 2013-02-27 | $6.81B 10-K · filed 2012-02-29 |
| 2011-09-30 | $3.97B 10-Q · filed 2011-11-04 | |
| 2011-06-30 | $6.61B 10-Q · filed 2011-08-08 | |
| 2011-03-31 | $1.71B 10-Q · filed 2011-05-10 | |
| 2010-12-31 | $4.12B 10-K · filed 2012-02-29 | |
| 2010-09-30 | $4.42B 10-Q · filed 2010-11-08 | |
| 2010-06-30 | $3.19B 10-Q · filed 2010-08-09 | |
| 2009-12-31 | $3.44B 10-K · filed 2011-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |